Article
Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer.
Critical reviews in oncology/hematology - 1 Jan 2022
Xu Dechen, Li Jie, Wang Dong, Zhou Li, Jin Jiahuan, Wang Yadong
Abstract excerpt
As a potential biomarker to predict the response to immunotherapy, tumor mutation burden (TMB) which can be estimated by the cancer gene panel (CGP) has received considerable attention. However, it is not clear which CGP is better in predicting the efficacy of immunotherapy. To evaluate the twelve CGPs, we compared them on 13 datasets of melanoma and non-small cell lung cancer (NSCLC) from the perspective of gene...
Topics
Join the communities discussing this publication.